Fresenius SE & Co. KGaA
Consolidated segment reporting
by business segment
enlarge| Fresenius Medical Care | Fresenius Kabi | Fresenius Helios | Fresenius Vamed | Corporate/Other1 | Fresenius Group | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € in millions | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change |
| 1 Including special items from the acquisition of APP Pharmaceuticals, Inc. The consolidated segment reporting by business segment is an integral part of the notes. The following notes are an integral part of the consolidated financial statements. |
||||||||||||||||||
| Sales | 9,192 | 9,091 | 1% | 3,964 | 3,672 | 8% | 2,665 | 2,520 | 6% | 737 | 713 | 3% | -36 | -24 | -50% | 16,522 | 15,972 | 3% |
| thereof contribution to consolidated sales | 9,177 | 9,088 | 1% | 3,916 | 3,629 | 8% | 2,665 | 2,520 | 6% | 737 | 713 | 3% | 27 | 22 | 23% | 16,522 | 15,972 | 3% |
| thereof intercompany sales | 15 | 3 | -- | 48 | 43 | 12% | 0 | 0 | - | - | -- | -63 | -46 | -37% | 0 | 0 | ||
| contribution to consolidated sales | 56% | 57% | 24% | 23% | 16% | 16% | 4% | 4% | 0% | 0% | 100% | 100% | ||||||
| EBITDA | 1,891 | 1,830 | 3% | 955 | 893 | 7% | 369 | 318 | 16% | 51 | 49 | 4% | -29 | -33 | 12% | 3,237 | 3,057 | 6% |
| Depreciation and amortization | 400 | 379 | 6% | 152 | 156 | -3% | 99 | 83 | 19% | 7 | 8 | -13% | 16 | 13 | 23% | 674 | 639 | 5% |
| EBIT | 1,491 | 1,451 | 3% | 803 | 737 | 9% | 270 | 235 | 15% | 44 | 41 | 7% | -45 | -46 | 2% | 2,563 | 2,418 | 6% |
| Net interest | -213 | -211 | -1% | -278 | -279 | 0% | -51 | -55 | 7% | 2 | 2 | 0% | 9 | -23 | 139% | -531 | -566 | 6% |
| Income taxes | -432 | -436 | 1% | -145 | -142 | -2% | -43 | -37 | -16% | -11 | -12 | 8% | 27 | 46 | -41% | -604 | -581 | -4% |
| Net income attributable to Fresenius SE & Co. KGaA | 770 | 738 | 4% | 354 | 294 | 20% | 163 | 131 | 24% | 34 | 30 | 13% | -631 | -571 | -11% | 690 | 622 | 11% |
| Operating cash flow | 1,039 | 1,032 | 1% | 462 | 567 | -19% | 294 | 311 | -5% | -83 | 47 | -- | -23 | -46 | 50% | 1,689 | 1,911 | -12% |
| Cash flow before acquisitions and dividends | 629 | 649 | -3% | 289 | 401 | -28% | 138 | 150 | -8% | -89 | 38 | -- | -36 | -60 | 40% | 931 | 1,178 | -21% |
| Total assets | 15,096 | 12,793 | 18% | 7,282 | 6,860 | 6% | 3,495 | 3,270 | 7% | 594 | 549 | 8% | -146 | 105 | -- | 26,321 | 23,577 | 12% |
| Debt | 5,573 | 4,400 | 27% | 4,395 | 4,298 | 2% | 1,104 | 1,096 | 1% | 44 | 16 | 175% | -1,317 | -1,026 | -28% | 9,799 | 8,784 | 12% |
| Capital expenditure, gross | 429 | 395 | 9% | 177 | 174 | 2% | 157 | 166 | -5% | 7 | 9 | -22% | 13 | 14 | -7% | 783 | 758 | 3% |
| Acquisitions, gross/investments | 1,429 | 596 | 140% | 11 | 31 | -65% | 45 | 13 | -- | 3 | 5 | -40% | 124 | -1 | -- | 1,612 | 644 | 150% |
| Research and development expenses | 80 | 73 | 10% | 162 | 143 | 13% | - | - | -- | 0 | 0 | 25 | 28 | -11% | 267 | 244 | 9% | |
| Employees (per capita on balance sheet date) | 83,476 | 77,442 | 8% | 24,106 | 22,851 | 5% | 37,198 | 33,321 | 12% | 3,724 | 3,110 | 20% | 847 | 828 | 2% | 149,351 | 137,552 | 9% |
| Key figures | ||||||||||||||||||
| EBITDA margin | 20.6% | 20.1% | 24.1% | 24.3% | 13.8% | 12.6% | 6.9% | 6.9% | 19.6% | 19.1% | ||||||||
| EBIT margin | 16.2% | 16.0% | 20.3% | 20.1% | 10.1% | 9.3% | 6.0% | 5.8% | 15.5% | 15.1% | ||||||||
| Depreciation and amortization in % of sales | 4.4% | 4.2% | 3.8% | 4.2% | 3.7% | 3.3% | 0.9% | 1.1% | 4.1% | 4.0% | ||||||||
| Operating cash flow in % of sales | 11.3% | 11.4% | 11.7% | 15.4% | 11.0% | 12.3% | -11.3% | 6.6% | 10.2% | 12.0% | ||||||||
| ROOA | 12.0% | 12.5% | 12.4% | 11.9% | 8.4% | 7.8% | 16.0% | 22.2% | 10.9% | 11.6% | ||||||||
by region
| Europe | North America | Asia-Pacific | Latin America | Africa | Fresenius Group | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € in millions | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change | 2011 | 2010 | Change |
| The consolidated segment reporting by region is an integral part of the notes. The following notes are an integral part of the consolidated financial statements. |
||||||||||||||||||
| Sales | 6,919 | 6,515 | 6% | 6,762 | 7,020 | -4% | 1,582 | 1,307 | 21% | 899 | 814 | 10% | 360 | 316 | 14% | 16,522 | 15,972 | 3% |
| contribution to consolidated sales | 42% | 41% | 41% | 44% | 10% | 8% | 5% | 5% | 2% | 2% | 100% | 100% | ||||||
| EBIT | 758 | 723 | 5% | 1,382 | 1,347 | 3% | 251 | 205 | 22% | 125 | 107 | 17% | 47 | 36 | 31% | 2,563 | 2,418 | 6% |
| Depreciation and amortization | 322 | 294 | 10% | 268 | 265 | 1% | 50 | 47 | 6% | 29 | 27 | 7% | 5 | 6 | -17% | 674 | 639 | 5% |
| Total assets | 9,759 | 8,935 | 9% | 13,670 | 12,152 | 12% | 1,888 | 1,610 | 17% | 877 | 755 | 16% | 127 | 125 | 2% | 26,321 | 23,577 | 12% |
| Capital expenditure, gross | 422 | 400 | 6% | 210 | 223 | -6% | 69 | 73 | -5% | 71 | 52 | 37% | 11 | 10 | 10% | 783 | 758 | 3% |
| Acquisitions, gross/investments | 924 | 267 | -- | 596 | 277 | 115% | 75 | 89 | -16% | 17 | 11 | 55% | - | - | -- | 1,612 | 644 | 150% |
| Employees (per capita on balance sheet date) | 74,415 | 66,179 | 12% | 47,701 | 46,082 | 4% | 13,134 | 12,258 | 7% | 12,754 | 11,726 | 9% | 1,347 | 1,307 | 3% | 149,351 | 137,552 | 9% |
Continue reading:
Notes
Notes